TABLE 4.
Pomotrelvir antiviral activity against SARS-CoV-2 clinical variants in A549-AT cells
| SARS-CoV-2 variant | a EC50 | a EC90 | ||
|---|---|---|---|---|
| Mean (nM, SD) | Mean fold | Mean (nM, SD) | Mean fold | |
| D614G B.1 (ancestral) | 151 (72) | − | 547 (377) | − |
| Alpha | 95 (22) | 0.6 | 144 (9) | 0.3 |
| Epsilon | 195 (14) | 1.3 | 777 (65) | 1.4 |
| Delta | 251 (42) | 1.7 | 425 (110) | 0.8 |
| AY.20 Delta | 374 (19) | 2.5 | 672 (55) | 1.2 |
| Mu | 73 (15) | 0.5 | 195 (104) | 0.4 |
| BA.1.1 Omicron | 94 (4) | 0.6 | 213 (23) | 0.4 |
| BA.2 Omicron | 139 (63) | 0.9 | 668 (486) | 1.2 |
| BA.2.12.1 Omicron | 60 (2) | 0.4 | 171 (10) | 0.3 |
| BA.4.1 Omicron | 244 (145) | 1.6 | 1120 (768) | 2.0 |
| BA.5.2.1 Omicron | 256 (174) | 1.7 | 1270 (1070) | 2.3 |
a
Mean from 2 to 6 experiments.